Navigation Links
New therapy substitutes missing protein in those with muscular dystrophy
Date:5/26/2009

Researchers at the University of Minnesota Medical School have discovered a new therapy that shows potential to treat people with Duchenne muscular dystrophy, a fatal disease and the most common form of muscular dystrophy in children.

In the mouse model, researchers were able to substitute for the missing protein dystrophin, which forms a key part of the framework that holds muscle tissue together that results in the disease, effectively repairing weakened muscle tissue.

Researchers injected dystrophic mice with a protein called utrophin a very close relative of dystrophin that was modified with a cell-penetrating tag, called TAT.

The study is the first to establish the efficacy and feasibility of the TAT-utrophin-based protein as a viable therapy for the treatment of muscular dystrophy as well as cardiac muscle diseases caused by loss of dystrophin.

The research is published in the May 26, 2009 issue of PLoS Medicine.

"This unique approach can replace the missing protein without the complexities of gene replacement or stem cell approaches," said James Ervasti, Ph.D., principal investigator of the study and a professor in the Department of Biochemistry, Molecular Biology & Biophysics.

Muscular dystrophy causes the muscles in the body to progressively weaken. Duchenne is the most common and severe form of childhood muscular dystrophy. About one of 3,500 boys are born with the crippling disease. Symptoms usually begin in children who are 2 to 3 years-old, most are in a wheelchair by age 12, and many who have the disease pass away by their late teens to early 20s. Current treatment, limited to corticosteroids, are minimally effective and can cause serious side effects.

Research underway to battle muscular dystrophy with gene therapy and stem cell treatment shows promise, but major hurdles must be overcome before these approaches are viable in human patients, Ervasti said.

Delivering treatment to every muscle cell via gene therapy or stem cells is difficult because muscle tissue makes up such a large portion of the human body. Furthermore, the immune system may reject the cell or gene treatment because patients would treat the newly introduced cells or genes as a foreign substance.

Ervasti's method may conquer both of those problems. Upon injection, the TAT-utrophin combination spreads around the entire body efficiently and is able to penetrate the muscle cell wall to substitute for missing dystrophin. Because every cell in the body makes utrophin naturally, TAT-utrophin circumvents immunity issues associated with other therapeutic approaches.

"Our protein replacement approach most directly and simply addresses the cause of Duchenne muscular dystrophy," Ervasti said.

This new method is not a cure for muscular dystrophy. Rather, it would be a therapy most likely administered on a regular basis. If the treatment works in larger animal models and humans, it's most likely researchers would develop a drug for patients. Ervasti is hopeful the therapy can move into human clinical trials within 3 years.


'/>"/>

Contact: Nick Hanson
hans2853@umn.edu
612-624-2449
University of Minnesota
Source:Eurekalert

Related biology news :

1. Gene therapy could expand stem cells promise
2. Breakthrough in radiotherapy promises targeted cancer treatment
3. From cars to cancer: UH professor employs auto industry tools for tumor therapy
4. Hebrew University researchers neutralize tumor growth in embryonic stem cell therapy
5. Moving gene therapy forward with mobile DNA
6. Simulated gene therapy
7. Early administration of antiretroviral therapy can improve survival
8. Stem cell therapy makes cloudy corneas clear, according to Pitt researchers
9. Gene therapy appears safe to regenerate gum tissue
10. Two-day symposium in Baltimore to tackle the promises and perils of proton radiotherapy
11. CSHL team develops mouse models of leukemia that predict response to chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert in ... media edge server, the M820, which features the company,s hybrid codec ... provided by Tera Probe, Inc., will be showcased during the upcoming ... NAB show at the Las Vegas Convention ... Click ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
Breaking Biology News(10 mins):
(Date:7/17/2017)... ... July 17, 2017 , ... ... long-standing innovation strategy. A website (openinnovation.pioneer.com) dedicated to connecting third-party innovators ... – trait discovery, plant breeding, enabling technologies, biologicals and digital solutions. , “DuPont ...
(Date:7/14/2017)... (PRWEB) , ... July 14, 2017 , ... ... conscious EMS company . Sonic Manufacturing Technologies has installed a solar system on ... in a three-year period,” the President of Sonic, Kenneth Raab stated. The company’s ...
(Date:7/13/2017)... ... 2017 , ... Thousands of pilots from across the country will visit the ... Pilots come to Muncie to compete in various categories of model flying competition. Each ... in world championships. , RC Pylon (July 14-21): One of the most fun competitions ...
(Date:7/13/2017)... ... July 13, 2017 , ... Frederick’s first and ... robust growth in the past year after an intensive restructuring. Under the leadership ... Programs and expanded its board of directors to revitalize the organization. As a ...
Breaking Biology Technology: